Benitec Swaps Auditor: Baker Tilly Out, EY In
BNTC is trading near its 52-week low of $9.255 (4.2% above the low).
Summary
Benitec Biopharma replaced Baker Tilly with Ernst & Young as its independent auditor, citing good governance. No disagreements or adverse opinions were reported; the prior material weakness was already remediated.
Key Events · Corporate Governance and Compliance · BNTC
-
Auditor Change Announced
On September 18, 2026, the Audit Committee dismissed Baker Tilly US, LLP and appointed Ernst & Young LLP for the fiscal year ending June 30, 2027.
-
No Disagreements or Adverse Opinions
Baker Tilly's audit reports for FY2025 and FY2026 contained no adverse opinion, disclaimer, or qualification on going concern, scope, or accounting principles.
-
Prior Material Weakness Remediated
The only reportable event was a material weakness in share-based compensation controls, disclosed in the FY2025 10-K and remediated as of June 30, 2026 per the FY2026 10-K.
-
EY Engagement Pending Acceptance
Formal engagement of EY remains subject to completion of EY's client acceptance process.
Analysis · BNTC · Life Sciences
After a six-year engagement, Benitec Biopharma dismissed Baker Tilly US, LLP and brought in Ernst & Young LLP for the fiscal year ending June 30, 2027. The filing confirms there were no disagreements or adverse opinions, and the only reportable event was a material weakness in share-based compensation controls that had already been remediated as of June 30, 2026. For a clinical-stage biotech with $180M in cash and an FDA pivotal design discussion underway, an auditor change can raise governance questions—though the clean opinion and remediation disclosure help mitigate that concern. The EY engagement remains subject to client acceptance, adding a minor execution risk.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNTC was trading at $9.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $336.3M. The 52-week trading range was $9.26 to $16.76. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.